This CPB has been revised to state that sodium phenylbutyrate is considered: (i) medically necessary for the treatment of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase; and (ii) experimental and investigational for the treatment of non-small-cell lung cancer, and oral squamous cell carcinoma.